Abstract

To investigate the effect of Qingyi decoction with modification adjunctive western medicine in the treatment of acute pancreatitis and the effect on high mobility group protein B1 and receptor for advanced glycation end products levels. In order to compare the improvement of clinical symptoms, traditional Chinese medicine evidence score, inflammatory factor levels, gastrointestinal hormone levels, and serum. 108 patients with acute pancreatitis treated in our hospital from January 2021 to January 2022 were chosen and randomly divided into the research group (n=54, treated with conventional western medicine) and the control group (n=54, treated with Qingyi decoction with modification on top of conventional western medicine). The length of hospital stay, acute physiological and chronic health status scores, and the times it took for abdominal pain, bloating, gas, and pressure to go away were all lower in the research group than in the control group (p<0.05). Following treatment, the research group had lower scores for abdominal discomfort, fullness, dryness, and firmness, nausea, vomiting, tidal fever, dry mouth and thirst, and short and red urine than the control group (p<0.05). Following therapy, the research group's levels of the inflammatory proteins tumor necrosis factor, hypersensitive C-reactive protein, and interleukin-6 were all lower than those of the control group (p<0.05). Following treatment, the levels of motilin were greater in the research group than in the control group (p<0.05), and the levels of gastrointestinal inhibitory peptide, vasoactive intestinal peptide, and gastrointestinal inhibitory peptide were lower in the research group than in the control group (p<0.05). Following treatment, the research group's levels of high mobility group protein B1 and receptor for advanced glycation end products were both lower than those of the control group (p<0.05). With some modifications, Qingyi decoction is effective in the treatment of acute pancreatitis with western medicine. It has significant effects on clinical symptoms, the inflammatory response, and high mobility group protein B1 and receptor for advanced glycation end products levels, and is highly valuable for clinical use and promotion.